A new study found stage 1 pancreatic cancer is more likely to be identified with the tumor marker CA 19-9 and targeted endoscopic ultrasound than with standard means of detection, according to a news release the American Society for Gastrointestinal Endoscopy.
The study, appearing in the society's journal, GIE: Gastrointestinal Endoscopy, found that a patient detected with the new screening protocol was alive without evidence of recurrence three years after surgical resection.
The study said costs of the new screening protocol were acceptable: $8,431 to detect pancreatic neoplasia and $41,133 to detect pancreatic cancer.
Read the American Society for Gastrointestinal Endoscopy release on pancreatic cancer detection (pdf).
Related Articles on Pancreatic Cancer:
Expert Cautions Findings on Pancreatic Cancer Screening
New Research Supports Previous Studies Aspirin Reduces Risk of CRC
Study: Endoscopic Ultrasound Associated With Improved Pancreatic Cancer Outcomes